粪菌移植降低CD4/CD8比值低的抗逆转录病毒治疗HIV感染者免疫激活:单盲随机安慰剂对照Gutsy研究方案(CIHR/CTN PT038)
Gutsy研究是一项单盲、随机、安慰剂对照临床试验,评估粪菌移植(FMT)对接受抗逆转录病毒治疗(ART)超过3年、病毒载量低于50拷贝/mL、CD4计数高于200细胞/mL且CD4/CD8比值低于1.0的HIV感染者肠道上皮通透性血浆标志物的影响。治疗组10人接受肠道清洁后两次高剂量FMT胶囊(30至40粒,间隔3周),安慰剂组10人接受肠道清洁后微晶纤维素胶囊。主要目的是评估FMT对肠道上皮通透性血浆标志物的效应。
要点
- Gutsy研究纳入ART超过3年、病毒载量低于50拷贝/mL、CD4计数高于200细胞/mL、CD4/CD8比值低于1.0的HIV感染者。
- 治疗组10人接受肠道清洁后两次高剂量FMT胶囊(30至40粒,间隔3周),安慰剂组10人接受肠道清洁后微晶纤维素胶囊。
- 主要目的是评估FMT对肠道上皮通透性血浆标志物的效应,次要目的包括微生物易位、免疫激活和HIV潜伏库生物标志物。
核心结论
- 研究假设大剂量FMT胶囊而非安慰剂胶囊将增加接受ART的HIV感染者肠道有益微生物丰度,从而降低肠道损伤标志物并减少免疫激活。
- Gutsy先导性研究的结果将为评估FMT对HIV感染者免疫激活影响的大型确定性随机临床试验的样本量计算提供依据。
研究设计与样本
- Gutsy研究是一项单盲、随机、安慰剂对照临床试验,纳入接受ART超过3年、病毒载量低于50拷贝/mL、CD4计数高于200细胞/mL且CD4/CD8比值低于1.0的HIV感染者。
- 治疗组10名参与者接受肠道清洁后两次高剂量FMT胶囊(30至40粒,间隔3周),安慰剂组10名参与者接受肠道清洁后微晶纤维素胶囊(重量和颜色等效,相同时间进程给药)。
- 在外周血单核细胞(PBMC)和粪便样本于每次访视时采集:肠道清洁前(基线1)、首次FMT/安慰剂前(基线2)和第2次FMT/安慰剂前(访视4)、首次FMT/安慰剂后6周(访视5)和12周(访视6);结肠活检在可选子研究的访视3和访视6获取。
关键数值与推荐
- 主要目的是评估FMT对肠道上皮通透性血浆标志物的效应。
- 次要目的包括微生物易位、免疫激活和HIV潜伏库生物标志物。
- 试验注册:ClinicalTrials.gov NCT06022406,注册日期2024年8月1日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite antiretroviral therapy (ART) controlling HIV viral replication, people with HIV (PWH) remain at risk for inflammatory non-AIDS comorbidities. Factors contributing to comorbidities in PWH on ART include spontaneous release of HIV products, CMV co-infection, microbial translocation, and gut dysbiosis, each driving systemic T-cell activation. In addition to ART, novel gut microbiota-modulating therapies could reduce epithelial gut permeability, microbial translocation, and immune activation. Fecal microbiota transplantation (FMT) from healthy volunteer is a promising therapy to counteract dysbiosis, protect from gut barrier damage, and lower systemic immune activation. METHODS: The Gutsy study is a single-blind, randomized, placebo-controlled clinical trial evaluating the effects of FMT in PWH on ART for more than 3 years, with a viral load below 50 copies/mL, a CD4 count above 200 cells/mL, and a CD4/CD8 ratio below 1.0. All participants undergo a bowel cleanse before receiving FMT or placebo capsules. In the treatment group, 10 participants receive a bowel cleanse then two high doses of FMT delivered via 30 to 40 capsules twice, 3 weeks apart. The placebo group of 10 participants receive a bowel cleanse and capsules filled with microcrystalline cellulose for equivalence in weight and color, administered under the same time course. Peripheral blood mononuclear cells (PBMCs) and stool samples are collected at each visit: before bowel cleanse (baseline 1), before the first (baseline 2) and the 2nd (visit 4) FMT/placebo, 6 weeks (visit 5) and 12 weeks (visit 6) after the first FMT/placebo; colon biopsies are obtained at visits 3 and 6 in an optional sub-study. The primary objective is to assess the effect of FMT on plasma markers of gut epithelial permeability. Secondary objectives include microbial translocation, immune activation, and HIV latent reservoir biomarkers. DISCUSSION: We hypothesize that large-dose FMT in capsules, but not placebo capsules, will increase the abundance of beneficial microbes in the gut of PWH on ART, leading to decreased gut damage markers and reduced immune activation. The results of the Gutsy pilot study will inform for the calculation of sample size of larger definitive randomized clinical trials assessing the influence of FMT on immune activation in PWH. TRIAL REGISTRATION: ClinicalTrials.gov NCT06022406. Registered on 2024-08-01. https://clinicaltrials.gov/study/NCT06022406?cond=HIV&term=Gutsy&rank=1 .
引用
- Isnard S, Berini CA, Parvathy SN, et al. Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038). Trials. 2025. PMID: 41390455. doi:10.1186/s13063-025-09345-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。